• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

磷脂酰肌醇3-激酶抑制剂的β和δ亚型特异性结合机制的理论研究

Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.

作者信息

Zhu Jingyu, Pan Peichen, Li Youyong, Wang Man, Li Dan, Cao Biyin, Mao Xinliang, Hou Tingjun

机构信息

Cyrus Tang Hematology Center, Soochow University, Suzhou, Jiangsu 215123, China.

出版信息

Mol Biosyst. 2014 Mar 4;10(3):454-66. doi: 10.1039/c3mb70314b. Epub 2013 Dec 16.

DOI:10.1039/c3mb70314b
PMID:24336903
Abstract

Phosphoinositide 3-kinase (PI3K) is known to be closely related to tumorigenesis and cell proliferation, and controls a variety of cellular processes, including proliferation, growth, apoptosis, migration, metabolism, etc. The PI3K family comprises eight catalytic isoforms, which are subdivided into three classes. Recently, the discovery of inhibitors that block a single isoform of PI3K has continued to attract special attention because they may have higher selectivity for certain tumors and less toxicity for healthy cells. The PI3Kβ and PI3Kδ share fewer studies than α/γ, and therefore, in this work, the combination of molecular dynamics simulations and free energy calculations was employed to explore the binding of three isoform-specific PI3K inhibitors (COM8, IC87114, and GDC-0941) to PI3Kβ or PI3Kδ. The isoform specificities of the studied inhibitors derived from the predicted binding free energies are in good agreement with the experimental data. In addition, the key residues critical for PI3Kβ or PI3Kδ selectivity were highlighted by decomposing the binding free energies into the contributions from individual residues. It was observed that although PI3Kβ and PI3Kδ share the conserved ATP-binding pockets, individual residues do behave differently, particularly the residues critical for PI3Kβ or PI3Kδ selectivity. It can be concluded that the inhibitor specificity between PI3Kβ and PI3Kδ is determined by the additive contributions from multiple residues, not just a single one. This study provides valuable information for understanding the isoform-specific binding mechanisms of PI3K inhibitors, and should be useful for the rational design of novel and selective PI3K inhibitors.

摘要

已知磷酸肌醇 3 -激酶(PI3K)与肿瘤发生和细胞增殖密切相关,并控制多种细胞过程,包括增殖、生长、凋亡、迁移、代谢等。PI3K 家族包含八种催化亚型,可细分为三类。最近,能够阻断单一 PI3K 亚型的抑制剂的发现持续吸引着特别关注,因为它们可能对某些肿瘤具有更高的选择性,对健康细胞的毒性更小。与α/γ相比,PI3Kβ和 PI3Kδ的研究较少,因此,在本研究中,采用分子动力学模拟和自由能计算相结合的方法来探究三种亚型特异性 PI3K 抑制剂(COM8、IC87114 和 GDC - 0941)与 PI3Kβ或 PI3Kδ的结合情况。从预测的结合自由能得出的所研究抑制剂的亚型特异性与实验数据高度吻合。此外,通过将结合自由能分解为各个残基的贡献,突出了对 PI3Kβ或 PI3Kδ选择性至关重要的关键残基。观察到尽管 PI3Kβ和 PI3Kδ共享保守的 ATP 结合口袋,但各个残基的行为确实有所不同,特别是对 PI3Kβ或 PI3Kδ选择性至关重要的残基。可以得出结论,PI3Kβ和 PI3Kδ之间的抑制剂特异性是由多个残基的累加贡献决定的,而不仅仅是单个残基。本研究为理解 PI3K 抑制剂的亚型特异性结合机制提供了有价值的信息,并且应该有助于新型和选择性 PI3K 抑制剂的合理设计。

相似文献

1
Theoretical studies on beta and delta isoform-specific binding mechanisms of phosphoinositide 3-kinase inhibitors.磷脂酰肌醇3-激酶抑制剂的β和δ亚型特异性结合机制的理论研究
Mol Biosyst. 2014 Mar 4;10(3):454-66. doi: 10.1039/c3mb70314b. Epub 2013 Dec 16.
2
Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption.同工型选择性磷脂酰肌醇 3-激酶抑制剂对破骨细胞的影响:对细胞骨架组织、存活和吸收的作用。
J Biol Chem. 2013 Dec 6;288(49):35346-57. doi: 10.1074/jbc.M113.507525. Epub 2013 Oct 16.
3
Mechanisms of PI3Kβ-selective inhibition revealed by reciprocal mutagenesis.PI3Kβ 选择性抑制机制的相互突变揭示。
ACS Chem Biol. 2013 Apr 19;8(4):679-83. doi: 10.1021/cb300666s. Epub 2013 Feb 6.
4
Structural Determinants of Isoform Selectivity in PI3K Inhibitors.PI3K 抑制剂的异构体选择性的结构决定因素。
Biomolecules. 2019 Feb 26;9(3):82. doi: 10.3390/biom9030082.
5
Atropisomerism by Design: Discovery of a Selective and Stable Phosphoinositide 3-Kinase (PI3K) β Inhibitor.设计中的对映异构体:选择性和稳定的磷酸肌醇 3-激酶(PI3K)β 抑制剂的发现。
J Med Chem. 2018 Aug 9;61(15):6858-6868. doi: 10.1021/acs.jmedchem.8b00797. Epub 2018 Jul 30.
6
Binding selectivity studies of phosphoinositide 3-kinases using free energy calculations.利用自由能计算研究磷酸肌醇 3-激酶的结合选择性。
J Chem Inf Model. 2012 Dec 21;52(12):3213-24. doi: 10.1021/ci3003057. Epub 2012 Nov 30.
7
Novel 6-aryl substituted 4-pyrrolidineaminoquinazoline derivatives as potent phosphoinositide 3-kinase delta (PI3Kδ) inhibitors.新型 6-芳基取代 4-吡咯烷氨基喹唑啉衍生物作为有效的磷酸肌醇 3-激酶 δ(PI3Kδ)抑制剂。
Bioorg Med Chem. 2018 May 1;26(8):2028-2040. doi: 10.1016/j.bmc.2018.03.002. Epub 2018 Mar 2.
8
Rational design of phosphoinositide 3-kinase α inhibitors that exhibit selectivity over the phosphoinositide 3-kinase β isoform.磷酸肌醇 3-激酶 α 抑制剂的合理设计,表现出对磷酸肌醇 3-激酶 β 同工型的选择性。
J Med Chem. 2011 Nov 24;54(22):7815-33. doi: 10.1021/jm2007084. Epub 2011 Oct 21.
9
Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα.发现新型氨基嘧啶类磷酸肌醇 3-激酶β(PI3Kβ)抑制剂,对 PI3Kα 具有选择性。
Bioorg Med Chem Lett. 2011 Dec 1;21(23):6977-81. doi: 10.1016/j.bmcl.2011.09.118. Epub 2011 Oct 8.
10
Dissecting isoform selectivity of PI3K inhibitors: the role of non-conserved residues in the catalytic pocket.剖析PI3K抑制剂的亚型选择性:催化口袋中非保守残基的作用。
Biochem J. 2008 Sep 15;414(3):383-90. doi: 10.1042/BJ20080512.

引用本文的文献

1
Design, synthesis and biological evaluation of novel morpholinopyrimidine-5-carbonitrile derivatives as dual PI3K/mTOR inhibitors.新型吗啉代嘧啶-5-腈衍生物作为双靶点PI3K/mTOR抑制剂的设计、合成及生物学评价
RSC Med Chem. 2024 Feb 2;15(2):733-752. doi: 10.1039/d3md00693j. eCollection 2024 Feb 21.
2
A multi-conformational virtual screening approach based on machine learning targeting PI3Kγ.一种基于机器学习靶向PI3Kγ的多构象虚拟筛选方法。
Mol Divers. 2021 Aug;25(3):1271-1282. doi: 10.1007/s11030-021-10243-1. Epub 2021 Jun 23.
3
Theoretical studies on the selectivity mechanisms of PI3Kδ inhibition with marketed idelalisib and its derivatives by 3D-QSAR, molecular docking, and molecular dynamics simulation.
通过 3D-QSAR、分子对接和分子动力学模拟研究已上市的 PI3Kδ 抑制剂idelalisib 及其衍生物的选择性机制。
J Mol Model. 2019 Jul 23;25(8):242. doi: 10.1007/s00894-019-4129-x.
4
Theoretical Studies on the Selectivity Mechanisms of Glycogen Synthase Kinase 3β (GSK3β) with Pyrazine ATP-competitive Inhibitors by 3DQSAR, Molecular Docking, Molecular Dynamics Simulation and Free Energy Calculations.基于三维定量构效关系、分子对接、分子动力学模拟和自由能计算对糖原合酶激酶3β(GSK3β)与吡嗪类ATP竞争性抑制剂选择性机制的理论研究
Curr Comput Aided Drug Des. 2020;16(1):17-30. doi: 10.2174/1573409915666190708102459.
5
The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity and .双重PI3K/mTOR抑制剂达可替尼具有抗肿瘤活性并且……(原文此处不完整)
Oncotarget. 2017 Dec 9;9(1):706-717. doi: 10.18632/oncotarget.23091. eCollection 2018 Jan 2.
6
A novel PI3K inhibitor PIK-C98 displays potent preclinical activity against multiple myeloma.一种新型PI3K抑制剂PIK-C98对多发性骨髓瘤显示出强大的临床前活性。
Oncotarget. 2015 Jan 1;6(1):185-95. doi: 10.18632/oncotarget.2688.
7
Computer-aided targeting of the PI3K/Akt/mTOR pathway: toxicity reduction and therapeutic opportunities.PI3K/Akt/mTOR信号通路的计算机辅助靶向:毒性降低与治疗机遇
Int J Mol Sci. 2014 Oct 20;15(10):18856-91. doi: 10.3390/ijms151018856.
8
A virtual screen identified C96 as a novel inhibitor of phosphatidylinositol 3-kinase that displays potent preclinical activity against multiple myeloma in vitro and in vivo.一项虚拟筛选将C96鉴定为磷脂酰肌醇3激酶的新型抑制剂,该抑制剂在体外和体内均对多发性骨髓瘤显示出有效的临床前活性。
Oncotarget. 2014 Jun 15;5(11):3836-48. doi: 10.18632/oncotarget.1657.